DPCG contributes to a US patent application in collaboration with KAAU
United States Patent Application 20240369557- BLOOD PROFILE ANALYSIS METHOD FOR IDENTIFICATION OF NEW DIABETES DIAGNOSTIC MARKERS IN SARS-COV-2 INFECTED PATIENTS PUBLISHED- 07/11/2024
Prof. Mirza R. Baig along with the group of researchers from King Abdul Aziz University (KAAU), Jeddah, Saudi Arabia conducted a study among SARS-COV-2 patients and analyzed blood profile analysis method for identifying new diabetes diagnostic markers.
A patent has been applied by KAAU as an intellectual property to protect the originality of the process.
The present invention relates to a study that examines the trends of long-term complications, particularly the incidence of type 2 diabetes mellitus (T2D), in the Saudi population following SARS-COV-2 infection and vaccination. The results showed a significant increase in HbA1c, urea, creatinine, alkaline phosphatase, lactate dehydrogenase, and triglycerides among diabetic patients compared to non-diabetic individuals. Notably, individuals with blood group O had the highest incidence of T2D. These findings suggest that SARS-COV-2 infection and vaccination are associated with the worsening of T2D symptoms and highlight the need for large-scale studies to understand the long-term metabolic complications of the COVID-19 pandemic, aiming to develop effective prevention and management strategies.
Prof. Dr. Mirza R. Baig was included in the patent application to help in research design and biostatistics.
